RxDoctor Payments Data

Hakam Asaad, MD

Neuromuscular Medicine · Dallas, TXNPI 1871603241

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.

$8,396in general payments, 2019–2025

Across 408 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Genentech USA, Inc.$801
  • Jazz Pharmaceuticals Inc.$417
  • UCB, Inc.$400
  • Biogen$350
  • Grifols USA, LLC$289
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$8,29699%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$491,677
Medicare patients
436
Services billed
10,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NourianzIstradefylline17$33,898
QuliptaAtogepant27$30,416
Nurtec OdtRimegepant Sulfate14$26,666
AptiomEslicarbazepine Acetate16$22,942
RytaryCarbidopa/Levodopa19$14,767
Lacosamide40$11,901
TrintellixVortioxetine Hydrobromide20$10,015
Rivastigmine44$9,043
Memantine Hcl222$7,865
Gabapentin301$6,459
Carbidopa-Levodopa ErCarbidopa/Levodopa77$5,034
Donepezil Hcl285$3,245
Propranolol Hcl ErPropranolol Hcl82$2,822
Eszopiclone144$2,711
Pregabalin125$2,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Nourianz$126$33,89817 claims
AbbVieQulipta$1,307$30,41627 claims
PfizerNurtec Odt$200$26,66614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Texason file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →